According to the authors more than 50% of patients may have experienced more than 50% motor function improvement
Researchers in Peru collected stem cells of unspecified type from the bone marrow of 53 patients with Parkinson’s disease (37 men and 16 women, age 38-81 years, duration of disease 1-25 years) and reintroduced them via an intra-arterial catheter into the arteries that supply blood to the substantia nigra in the brain, the area affected by the disease.
The patients were followed-up on average for 7 months.
They experienced improvement in motor symptoms on the UPDRS scale on average by 51.1%, as well as important improvements in the score of other scales (Hoehn & Yahr, Schwab & England, Northwestern University Disability Scale, PD Quality of Life scale). An unspecified number of patients developed involuntary movements and had to reduce dopaminergic therapy. No adverse events were reported.
Unfortunately the study was open-label, without a control group and, with the exception of only 8 patients, no objective neuroimaging data were collected.